Saturday, October 31, 2026

Everbridge Stock Over 22% Down So Far On Tuesday

Everbridge Stock Over 22% Down So Far On Tuesday

Everbridge, a globally renowned software firm, experienced a significant drop in share values on Tuesday as a result of a generally negative trading trend. The sudden drop was surprising, particularly given that the overall decline in the NASDAQ was a mere 1.12%. This leaves Everbridge greatly behind their 52-week high, ushering in a potentially challenging period for the tech company.

About Everbridge

Recognized as 3n Global, Inc., when it was founded in 2002, the Massachusetts-based company offers software applications worldwide. Their SaaS-based Critical Event Management platform is leveraged by diverse organizations, ranging from technology to energy, financial services, and healthcare. In 2009, the company underwent a name change, from 3n Global Inc to Everbridge Inc.

Everbridge's Profitability Ratios

Everbridge managed to achieve an earnings per share (EPS) of 1.57 for the trailing 12 months. However, its return on equity (ROE), a gauge that measures profitability concerning shareholder’s equity, stood at a disconcerting negative -18.9% during this period.

Stock Status according to Stochastic Oscillator

As per the stochastic oscillator - a well-accepted industry indicator that distinguishes between overbought and oversold conditions, Everbridge’s shares are presently in an oversold state. This status demands investors and traders' closer examination in seek of possible buying openings.

Everbridge’s Recovery Potential

Despite the recent downward tendency, Everbridge’s stock price performs better than its 52-week low. With the significant gap between the company's 52-week high and current values, a recovery might still be feasible if management can guide their performance upwards.

The Importance of Financial Literacy

Financial literacy, which includes understanding market fluctuations and indicators, is essential for making knowledgeable investment decisions. Even when the market faces a downturn, investors should view this as a potential opportunity, especially those who believe in Everbridge's long-term possibilities. However, it's worth noting that all decisions must be well informed, as Everbridge's unfavourable ROE ratio should act as a reminder for investors to do thorough research before making any commitments.

More news about Everbridge (EVBG).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com